Nexalin stock surged as new clinical data showed its Gen-2 device improved cognition and brain connectivity in mild Alzheimer’s patients without safety concerns.
Nexalin Technology Inc. (NASDAQ:NXL) stock spiked on Wednesday, with a massive session volume of 167.9 million compared to the average volume of 972.2 thousand, as per data from Benzinga Pro.
The company announced the publication of additional positi… [2247 chars]
Source: Benzinga | Published: 2025-10-08T18:45:32Z
Credit: Benzinga
